Zai Lab Q2 revenue falls 3% to $106.3M; net loss widens 25% on FX gains

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

• high

  Net loss widened 25% to $50.8M ($0.05/share) despite a 39% wider operating loss ($76.5M), as $15.1M in foreign-currency gains (RMB appreciation) offset operational deterioration.

  MD&A: Operating Loss & FX Gains verify on EDGAR →
• high

  ZEJULA revenue fell 22% YoY to $32.1M as hospitals shifted to generic olaparib following volume-based procurement

  MD&A: Product Revenue verify on EDGAR →
• high

  KarXT, the first novel-mechanism schizophrenia therapy in 70+ years, launched in China in June 2026; company preparing for NRDL inclusion in 2027.

  MD&A: KarXT Launch verify on EDGAR →